In the office, Chen Changan raised his eyebrows proudly and said indifferently: "If they want to, just drag it out, we have the initiative anyway."

"I guess it will take 50 or 8 years for Medtronic to create a real bio pacemaker. As for their desire to develop a product similar to our genetic agent, it may not be possible to study it in ten years."

Chen Changan smiled confidently. He was not a random speculation. Two or three years ago at the World Expo, Medtronic's vice president had been interviewed by the media and looked forward to the prospects of bio pacemakers.

In the words of that vice president, it will probably take more than ten years for Medtronic to develop a mature bio pacemaker. Even if he gives a discount, it will take at least seven or eight years for Medtronic's bio pacemaker program to be clinical.

As for the genetic agents that imitate Ruikang?

This thing is not a mechanical device, and can be disassembled. Once something like genetic medicine comes into contact with external gas, the molecular structure will change.

Even in a high-standard laboratory, it is not that simple to analyze the E. coli vector carrying the genes. Even if it is analyzed, researchers cannot reversely restore the re-edited gene fragments.

What's more, there is a special genome that extends the cell survival cycle exclusively provided by Chen Changan.

It takes several years to study the E. coli vector in genetic agents, and it may not take ten years to study it.

Techniques involving cellular and genetic levels are not that easy to imitate. Without relevant information and technical points, it is basically impossible to reverse the production process based on the finished product.

This time, Chen Changan did not ask the research center to publish a paper related to cardiomyocyte gene agents because this is a drug technology that needs to be strictly kept confidential and no relevant information can be leaked.

Currently, only the Nandou Scientific Research Center and Tiantan Biology are the ones who have the relevant information. Nandou is responsible for research and development, Tiantan Biology is responsible for production, and the self-built pharmaceutical production line of Ruikang's production center is also completely responsible for the scientific researchers on Nandou. Ruikang Medical's engineers and management have no relevant technical information.

Basically, the possibility of leaks is very low. Unless Wang Jia betrays, or the state-owned enterprise of Tiantan Biology, is a 25-year-old company, otherwise foreign companies such as Medtronic, may have to use the finished product for reverse research if they want to obtain the production technology of genetic agents.

Medtronic also favors black chicken mackerel. Originally, Huaxia Medical Equipment Company copied their products, but since Ruikang Medical made its mark in China, its status seems to have undergone some subtle changes.

The collagen suture at the beginning was a relatively low-end consumable, but since the Kirin invasive ventilator, Medtronic's scientific research department began to pay attention to the small company Ruikang.

After the artificial hematopoietic equipment emerged, four medical device research institutions under Medtronic purchased a batch and began to try reverse research and development.

This was the first time. American medical companies began to research a medical device from China, and the reverse engineering was not going well. After half a year of hard work, the progress was not even 10%, and they were stuck for a while.

Before they could figure out what tricks they had, Ruikang released this genetic agent that can replace pacemakers and cure pacemakers!

This time they were even more blinded. Genetics and drugs, strictly counted as medicines, do not belong to the field of medical devices!

Medical device giants such as Medtronic, St. Jude, and Baiduoli don’t even have the ability to follow the back and reverse. They can only grit their teeth and increase investment in the field of biopacifiers, trying to come up with a clinically capable biopacifier as soon as possible.

But how easy is it?

Chen Changan is now sitting firmly on Diaoyutai, and he is not in a hurry at all.

"Guan Kou, if the country that has not passed the listing approval is blocked, let's put it aside first, and there is no need to worry about it. However, public opinion still needs to continue to guide and cannot reduce their pressure."

"When the company's layout in the Middle East, Africa, Southeast Asia has been completed, then consider the European and American markets. I guess they won't last long by that time."

"It will be almost done if you delay one or two years. If you really delay three or five years, the pacemaker lifespan of a large number of patients will expire one after another. It is really possible that patients will undergo cross-border treatment on a large scale, and then the faces of governments in various countries will not be too good."

"Don't worry, it's good to delay for a year or two. It just so happens that the company can give it a buffer time and train a group of new people. At that time, it will be dispatched to various countries to establish offices and branches."

"But agents and dealers in European and American countries should contact early. Only these profit-oriented businessmen will not care whether the markets of Medtronic and other companies will be swallowed up by us. They only care about money."

"As long as we give enough benefits, they will also help us lobby the government, and it will be a good help if we use it well."

"To unite more friends, business will be easier."

Guan Kou nodded, wrote down Chen Changan's order, and took out another document and reported: "Mr. Chen, the 480-acre factory area around the production center has finally been negotiated."

"A total of more than 400 million yuan is sold in packages, including equipment in the factory, home appliances in the dormitory building, etc. We can settle in directly after purchasing it."

"We just don't use some production equipment, we need to deal with it, and then add a new production line."

"However, the factory buildings, dormitory buildings, canteens, and various infrastructures are complete, and the building age is not high. The longest one has only been used for five years."

Chen Changan looked at Guan Kou in surprise and said in confusion: "The 480 acres of industrial land, plus the supporting buildings, can only be acquired for 400 million yuan?"

Guan Kou smiled and explained, "This is the combined price of six factories near the production center. If you look at it separately, each company will not occupy a large area and the unit price is not very expensive."

"So the price of buying is much cheaper. The original offer was 600 million, but after a long negotiation and evaluation, it was finally talked about 400 million."

"Not bad!" Chen Changan nodded in approval and said with satisfaction: "400 million is already a good deal, and it is a great deal."

"Sign the contract as soon as possible, then reintegrate, re-adjust the layout, and integrate these six factories and our production center."

"By the way, let's draw another piece of land and prepare to build a production line for genetic medicine. Since the production center has expanded, we still need to build our own drug production line. Whether it is cardiomyocyte therapy drugs or drugs based on gene programming technology that may appear next, they will be used."
Chapter completed!